Abingdon Health plc

("Abingdon Health", the "Group" or the "Company")

CS (Lifesciences) Ltd contract win

Abingdon subsidiary wins >£500k contract

York, U.K. 8 January 2025: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), announces that its subsidiary company, CS (Lifesciences) Ltd, has won a contract with a major global diagnostics company for work relating to quality management systems and regulatory approvals. The contract will commence in March 2025 and continue for 12 months, providing revenue of >£500k spread across that period.

Abingdon Health acquired CS (Lifesciences) Ltd, a consultancy specialising in meeting compliance requirements in international IVD and medical device markets, in August 2024, broadening Abingdon's service offering and enabling the Group to fully support its customers in bringing their products from idea through to commercial success.

For more information on CS (Lifesciences) Ltd, see its brochure here.

Edwin Lindsay, Managing Director of CS (Lifesciences) Ltd said, "I am delighted that we can announce this contract win with a major entity in the medical diagnostics sector. It illustrates that our focussed skilled personnel are able to offer specialised expertise in quality and regulatory approval which is competitive and appealing to even the major players in the in vitro diagnostics sector."

Chris Yates, CEO of Abingdon said, "This contact win illustrates one aspect of Abingdon's service offering in the medical diagnostic sector and to the wider med-tech industry. Our full CDMO service, offering services to an international customer base, has been enhanced by our recent acquisition of CS (Lifesciences) Ltd, and I congratulate Edwin and the team on this contract win with a major diagnostics company."

Enquiries:

About Abingdon Health plc

Abingdon Health Group is a leading IVD and med-tech contract service provider offering its comprehensive services to an international customer base.

The Company's CDMO division offers lateral flow product development, technology transfer, manufacturing and regulatory support services to customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health's CDMO division has the internal capabilities to take lateral flow projects, in areas such as infectious disease and clinical testing, including companion diagnostics, animal health and environmental testing, from initial concept through to routine and large-scale manufacturing: from "idea to commercial success".

Abingdon's regulatory services companies, Compliance Solutions (Life Sciences) and IVDeology, provide a broad range of regulatory services to the in vitro diagnostic and wider medical device industry, to support customers in bringing products to market across a range of territories including the USA, EU and the UK. Our consultancy services range from design, implementation and maintenance of quality management systems, preparation of technical files for regulatory approvals, part-time and interim management support, auditing both internal and external suppliers, management reviews and presentations, training and mentoring.

Abingdon Health's Abingdon Simply Test range of self-tests is an e-commerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test e-commerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland, such as pharmacy chains.

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com